Posts in tag

generics


The ACCC has announced that it will not oppose the merger of generics companies Arrow and Apotex Once combined, the two companies would supply around half the market for generic …

Researchers have found public perception bias may lead to more frequent reporting of adverse events for generics A US study has explored whether adverse event reporting patterns are similar between …

The ACTU has attacked the government over the revived TPP, claiming it would drive up drug prices ACTU president Ged Kearney says that the Trans Pacific Partnership, which is set …

Time for costly medicine monopolies to go from TPP trade talks Belinda Townsend, Australian National University; Deborah Gleeson, La Trobe University; Hazel Moir, Australian National University; Joel Lexchin, University of …

Several options in the King Review Interim Report, if ever implemented, could put community pharmacy at risk, says the Guild The Guild says that from the time of the Review’s …

A plan to push GPs to prescribe generics has been flagged ahead of the Federal Budget On the ABC’s 7.30 program Monday, reporter Andrew Probyn investigated possible changes to prescribing …

The SHPA has welcomed the Grattan Institute report’s recommendations on price disclosure The Institute’s conclusion that Australian Government policies have not gone far enough or fast enough to reduce the …

Around 60 generic medicines have been granted price increases this month, including a 133% increase for a common antibiotic Through the Generic Medicines Working Group, the Generic and Biosimilar Medicines Association …

We take a look at the week in pharmacy news around the world US: Following controversy over the skyrocketing price in the US of Mylan’s EpiPen, the company has stated …

Initial claims have been dismissed, but there is an opportunity to make further submissions on both sides GlaxoSmithKline’s legal proceeding against Apotex and Generic Partners over its paracetamol products has …

The 2016 Budget confirms the significant ongoing PBS savings provided by generic medicines, and signals the government’s intent to streamline medicine regulation processes, says GBMA. The absence of further PBS …

Evergreening strategies delay market entry for generic medicines to the detriment of the Australian community and there is a lack of evidence to support extending market exclusivity for pharmaceuticals, according …